Medicaid and obesity drugs: why coverage varies by state and changes with budgets

Whether Medicaid pays for a GLP-1 prescribed for obesity depends on the state, and within a state it can depend on the year. This page explains why, gives the January 2026 picture, and shows how to check your own program.

The federal exclusion

Medicaid drug coverage is broad by default: a state that participates in the drug rebate program covers nearly every FDA-approved outpatient drug from a participating manufacturer. Federal law then lists a handful of categories a state may exclude or restrict anyway. "Agents when used for anorexia, weight loss, or weight gain" is one of them (42 U.S.C. 1396r-8(d)(2)). The same list is what Medicare Part D borrows to exclude weight-loss drugs from its standard benefit.

So a state that covers Wegovy or Zepbound for obesity has chosen to. A state that does not cover them has not broken any rule. And a state that covered them last year can stop this year with a budget line and a notice, which several did.

The exclusion is tied to the indication, not the molecule. Semaglutide as Ozempic and tirzepatide as Mounjaro, prescribed for type 2 diabetes, are covered in every state under the ordinary rules. The variation on this site's cards is about the obesity indication only.

The January 2026 picture

KFF's state map, published January 16, 2026 with data as of January 2026, counted 13 state fee-for-service programs covering GLP-1s for obesity: Delaware, Kansas, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, North Carolina, Rhode Island, Tennessee, Utah, Virginia and Wisconsin. That was down from 16 in October 2025. KFF notes that covering states typically require prior authorization, and that a few others were planning or considering coverage.

The movement in the preceding six months shows how fast this changes:

• Tennessee added coverage of obesity-management agents including Wegovy and Zepbound effective August 1, 2025, with prior authorization criteria and quantity limits, revised January 1, 2026.
• North Carolina lost coverage on October 1, 2025 during a budget stalemate and reinstated it effective December 12, 2025 under its September 30, 2025 criteria (Wegovy preferred; Zepbound and Saxenda non-preferred).
• Michigan kept coverage but from January 1, 2026 limited it to members with morbid obesity who have failed other interventions and the preferred agents, to avert bariatric surgery.
• California, New Hampshire, Pennsylvania and South Carolina ended coverage for the obesity indication effective January 1, 2026. California's Medi-Cal Rx notice removed Wegovy, Zepbound and Saxenda for weight loss while leaving under-21 review and other indications in place; Pennsylvania's change applied to adults 21 and over.
• Utah ran a limited pilot from July 1, 2025, which KFF marks separately.

Every state page carries the status for that state, the source, and its date. Where a state agency notice exists it replaces KFF for that state.

Fee-for-service versus managed care

KFF's map, and our cards, describe fee-for-service coverage: the state's own drug list. Most Medicaid members are in managed-care plans. In many states plans must follow the state preferred drug list for at least the major classes; in others plans run their own formularies within state limits. Two members in the same state can therefore see different answers. The preferred drug list explainer shows where the state list lives and where a plan's formulary lives, and what the notations mean.

Prior authorization in practice

Where coverage exists, expect criteria along these lines: a body mass index threshold (often the label's 30, or 27 with a weight-related condition, and sometimes higher, as Michigan and Virginia illustrate), documentation of a supervised lifestyle program, a trial of a preferred agent before a non-preferred one, and reauthorization that depends on documented weight loss. The exact numbers are in the state's PA criteria document, which is linked from its preferred drug list. Your prescriber submits the request; you can ask for a copy of the criteria and of the decision.

Children and EPSDT

Members under 21 are covered by the federal Early and Periodic Screening, Diagnostic and Treatment guarantee, which requires states to cover medically necessary treatment even when the adult benefit excludes it. Several of the January 2026 notices say so explicitly. A denied request for a teenager is reviewed under a different standard than one for an adult.

Compounded GLP-1s and Medicaid

State lists name FDA-approved products. Compounded semaglutide and tirzepatide are not FDA approved, and we are not aware of a state Medicaid program that lists them. If cost is the reason you are looking at compounded products, the GLP-1 Pricing Index compares brand self-pay programs with compounded offers, and the FormBlends cost report sets out what the programs actually charge.

How to check your own program today

1. Open your state's page on this site and read the Medicaid row and its source.
2. Open the state preferred drug list and search for semaglutide or tirzepatide; read the notation next to Wegovy and Zepbound, not next to Ozempic and Mounjaro.
3. If you are in a managed-care plan, open that plan's formulary and do the same search.
4. Call the member help line on your card and ask the question in one sentence: "Is Wegovy (or Zepbound) covered for weight management, and what are the prior authorization criteria?"